omniture
from common-pcom:html:key:en_segment_includes_overall_segment_header_shtml
PR Newswire: news distribution, targeting and monitoring

 

Increase your visibility.

The news stories with video and photo can get more clicks and readers are more likely to share the news with others. The click rate of news with multimedia can be increased by 77% at the most. More

We offer the following distribution services:

All Releases

Knowledge Center

JournalistBlogger

Visit PR Newswire Knowledge Center and read articles about tips and information of communication, PR and disclosure.

from common-pcom:html:key:en_segment_includes_releases_right_column_video_module_shtml

Featured Video

Follow Us on Social Media

PRN linkedin

PR Newswire on
LinkedIn

PRN Fackbook

PR Newswire on Facebook

PR Newswire Blog

PR Newswire Blog

PRN on Twitter

PRN on Twitter @PRNewswire
Asia

PRN on Sina

美通社资讯 @prnasia

Top Headline
from common-pcom:html:key:en_segment_includes_releases_top_story_shtml
SHANGHAI, Feb. 19, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that the European Medicines Agency (EMA) has completed the Pre-Approval Inspection (PAI) of the company's cGMP Drug Substance (DS) and Drug Product (DP) manufacturing facilities for the production of TaiMed Biologics' TrogarzoTM with no critical findings. WuXi Biologics will submit responses to the EMA inspection report in March 2019 and expects to obtain GMP certification for its facilities in May 2019.
from common-pcom:html:key:en_segment_includes_overall_segment_footer_shtml
Advanced Search
Search
  
  1. Products & Services
  2. News Releases
  3. Knowledge Center
  4. Journalists & Media
  5. Multimedia Theater
  6. Contact Us